Truvada/Kaletra HIV PEP combination is safe and effective with a low rate of discontinuations

Published: September 9, 2010

A post-exposure prophylaxis (PEP) combination of FTC/tenofovir (Truvada) with lopinavir/ritonavir (Kaletra) tablets is safe and generally well-tolerated, French investigators report in the online edition of the Journal of Acquired Immune Deficiency Syndromes. The researchers recommend that this combination should be the standard PEP regimen.

Few patients stopped taking their treatment because of side-effects. However, the investigators found that women were more likely to report gastrointestinal side-effects than men.

“Due to this good tolerability, the low discontinuation rate, the ease of use, TDF/FTC+LPV/r tablet formulation should be considered as the standard of care concerning HIV PEP”, comment the investigators.

In France – as in the United Kingdom and many other countries – the recommended treatment for both occupational and non-occupational PEP is two nucleoside reverse transcriptase inhibitors (NRTIs) and a ritonavir-boosted protease inhibitor.

Full text available at link below –

Leave a Reply